Ribociclib resistance management

Ribociclib (Ribociclib) is a targeted drug commonly used to treat breast cancer. However, drug resistance is an issue that may affect the efficacy of reboxil therapy. Since everyone's physique is different, their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the medication yourself.

By studying ribociclib-resistant cell lines or patient samples, the molecular mechanisms underlying resistance can be revealed. This could help develop new treatment strategies. In cases of resistance, combining other drugs may be an effective strategy. Combination with other targeted drugs, chemotherapy drugs, or immunotherapy may be considered to increase the therapeutic effect and overcome drug resistance issues. If mechanisms of resistance are understood, attempts can be made to develop new drugs that target these mechanisms. By targeting molecular targets related to drug resistance, the growth and survival of tumor cells can be inhibited. In the early stages of treatment, the risk of drug resistance can be reduced by controlling the dose and time of reboxil use and combining it with other treatment modalities. In addition, it is also important to regularly monitor the effects of treatment and adjust the treatment plan in a timely manner.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.